Ascendis Health Limited (JSE:ASC)
92.00
+3.00 (3.37%)
Sep 26, 2025, 5:00 PM SAST
Ascendis Health Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
575.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | - | - | - |
Jun 30, 2024 | 1.47B | -63.39M | -4.13% |
Jun 30, 2023 | 1.54B | -24.02M | -1.54% |
Jun 30, 2022 | 1.56B | -266.01M | -14.57% |
Jun 30, 2021 | 1.83B | -377.56M | -17.14% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Clicks Group | 46.80B |
Aspen Pharmacare Holdings | 43.36B |
Dis-Chem Pharmacies | 39.17B |
Netcare | 25.85B |
Life Healthcare Group Holdings | 26.73B |
Adcock Ingram Holdings | 9.76B |
AfroCentric Investment Corporation | 8.48B |
Labat Africa | 45.18M |
Ascendis Health News
- 26 days ago - Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 ... - GuruFocus
- 5 weeks ago - Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade - Seeking Alpha
- 7 weeks ago - Ascendis (ASND) Q2 2025 Earnings Call Transcript - The Motley Fool
- 2 months ago - Ascendis wins FDA approval for growth hormone deficiency treatment - Seeking Alpha
- 4 months ago - Ascendis rises after FDA priority review for genetic condition treatment - Seeking Alpha
- 4 months ago - Ascendis highlights long-term efficacy of Yorvipath for hypoparathyroidism - Seeking Alpha
- 6 months ago - Ascendis submits NDA for TransCon CNP for achondroplasia - Seeking Alpha
- 11 months ago - Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate - Seeking Alpha